Arbutus Biopharma Corp. reported cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025, down from $122.6 million at the end of 2024. Total revenue for the third quarter was $0.5 million, compared to $1.3 million in the same period last year, reflecting a decrease in license royalty revenues. Research and development expenses declined to $5.8 million from $14.3 million, while general and administrative expenses decreased to $3.0 million from $4.5 million, attributed to organizational streamlining and cost-cutting measures. The net loss for the quarter was $7.7 million, or $0.04 per share, compared to a net loss of $19.7 million, or $0.10 per share, in the third quarter of 2024. Business developments included a focus on advancing clinical programs for imdusiran and AB-101, organizational restructuring, and ongoing litigation with Moderna and Pfizer-BioNTech.